Meanwhile, CRJI's first cement production line, which was also designed to produce 2,500 tons per day, successfully achieved its production target of 1 million tons in 2008.
Chairman and CEO, Mr. Zhao Shouren stated. ``In response to the growing demand in our market, we are taking many initiatives to increase our production capacity. We engaged over 30 qualified, motivated and experienced technicians and workers to further strengthen our technical operation team in 2008. By increasing the capacity of our two production lines, we are able to further reduce fixed production costs and meet increasing demand among our customers. Despite the global slowdown, we expect to continue 2008's strong growth into 2009.''
What They Do: China Runji Cement, Inc. is one of the leading players in cement production and distribution. The Company's certified manufacturing facilities which contain cutting-edge technology and advanced equipment are capable of producing as much as 2 million tons of cement annually. Furthermore, the Company's solid distribution network and customer-orientated services have earned Runji's products a superior reputation among its customers.
How They Trade: CRJI has a 52 week high of $2.10 and a 52 week low of $0.20.
Human Genome Sciences (Nasdaq: HGSI) Closed at $1.88. Today announced its priority goals for 2009 and report on the Company's progress toward commercialization during a presentation by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 27th Annual JPMorgan Healthcare Conference in San Francisco on Wednesday, January 14. "2009 will be a pivotal year for HGS," said Mr. Watkins. "In December 2008, we reported the positive results of Albuferon's first Phase 3 trial in chronic hepatitis C. We will have the results of Albuferon's second Phase 3 trial in March. Assuming the second trial is also successful, we expect that global marketing applications will be filed in fall 2009."
What They Do: The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases.
How They Trade: HGSI has a 52 week high of $11.95 and a 52 week low of $1.20.
VisionChina Media (Nasdaq: VISN) Closed at $7.70. Today announced that the Company's efforts in collecting accounts receivable were successful in the fourth quarter of 2008. The Company received US$36.29 million in cash and US$0.59 million in notes receivables from its advertisers to settle their accounts receivable balances with the Company in the last quarter of 2008. The Company had net accounts receivable of US$43.7 million as of September 30, 2008.
What They Do: VisionChina Media operates an out-of-home advertising network on mass transportation systems, including buses and subways that reach over 26 million viewers each day in China, according to CTR Market Research.
How They Trade: VISN has a 52 week high of $25.60 and a 52 week low of $4.25.
Digital Ally (Nasdaq: DGLY) Closed at $2.92. Today announced that on a preliminary unaudited basis, its revenues for the year ended December 31, 2008 increased over 65% to approximately $32.5 million, compared with revenues of $19.4 million in 2007. The Company expects to report record earnings in 2008, exclusive of non-recurring income tax benefits recorded in 2007, although fourth quarter profitability will be significantly impacted by research and development expenses related to a number of new products to be introduced in coming months. The Company also provided guidance that management expects 2009 revenues to exceed $50.0 million, for an increase of more than 50% from last year's levels.
What They Do: Digital Ally, Inc. develops, manufactures and markets advanced technology products for law enforcement, homeland security and commercial security applications. The Company's primary focus is Digital Video Imaging and Storage.
How They Trade: DGLY has a 52 week high of $11.41 and a 52 week low of $2.57.
About SmallCapReview
SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/subscribe.htm. SCR is not a registered broker/dealer or financial advisor. Before making a purchase or sale of any securities featured on our website, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. SCR may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our website or within our reports. SCR has been compensated three thousand five hundred dollars by a third party Guidancemarketing for services with regards to CRJI. As with any stock, companies we select to profile involve a degree of investment risk and volatility. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies.
